Microbiological activity of bovhyaluronidaze azoximer against microbial biofilms | CMAC

Microbiological activity of bovhyaluronidaze azoximer against microbial biofilms

Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(4):487-495

​ Kozlov R.S., Tapalskiy D.V., Karpova E.V., Petrovskaya T.A., Kurkova A.A.
10.36488/cmac.2024.4.487-495
bovhyaluronidaze azoximer Staphylococcus aureus Staphylococcus epidermidis Candida albicans Enterococcus faecalis Escherichia coli biofilm
Section
Personal Experience
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(4):487-495

Objective.

To evaluate the ability of bovhyaluronidaze azoximer to destroy biofilms formed by clinical strains of microorganisms.

Materials and Methods.

The study included 50 clinical strains of Staphylococcus aureus (n = 25), Staphylococcus epidermidis (n = 6), Enterococcus faecalis (n = 8), Escherichia coli (n = 9), Candida albicans (n = 2). Antimicrobial susceptibility testing was performed using broth microdilution method. Biofilm formation culturing in presence of antibiotics, or bovhyaluronidaze azoximer, or their combinations was assessed in Mueller-Hinton broth and brain heart broth in 96-well plates. Biofilms were fixed with 2,5% glutaraldehyde solution, stained with 0,25% crystal violet solution, which is extracted by 33% acetic acid solution.

Results.

Bovhyaluronidaze azoximer can destroy the matrix of preformed biofilms of methicillin-resistant strains of S. aureus as well as S. epidermidis, E. coli, C. albicans in concentrations of 64–1000 IU/ml, while exerting a dose-depend effective.

Conclusions.

Bovhyaluronidaze azoximer combining with antibiotics will potentiate its antimicrobial effects by destroying the microbial biofilm matrix formed by microorganisms with multidrug resistance and facilitating the penetration of antibiotics to cellular targets.

Roman S. Kozlov

Smolensk State Medical University, Smolensk, Russia

Dmitry V. Tapalskiy

Institute of Physiology of the National Academy of Sciences of Belarus, Minsk, Belarus

Karpova E.V.

Gomel State Medical University, Gomel, Belarus

Tatyana A. Petrovskaya

Gomel State Medical University, Gomel, Belarus

Anastasia A. Kurkova

Smolensk State Medical University, Smolensk, Russia

  • 1. Maharjan G., Khadka P., Siddhi Shilpakar G., Chapagain G., Dhungana G.R. Catheter-associated urinary tract infection and obstinate biofilm producers. Can J Infect Dis Med Microbiol. 2018;2018:7624857. DOI: 10.1155/2018/7624857
  • 2. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013;(136):1-51. DOI: 10.1111/apm.12099
  • 3. Garnett J.A., Matthews S. Interactions in bacterial biofilm development: a structural perspective. Curr Protein Pept Sci. 2012;13(8):739-755. DOI: 10.2174/138920312804871166
  • 4. Moons P. Bacterial interactions in biofilms. Crit Rev Microbiol. 2009;35(3):157-168. DOI: 10.1080/10408410902809431
  • 5. Hall C.W., Mah T.F. Molecular mechanisms of biofilmbased antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276-301. DOI: 10.1093/femsre/fux010
  • 6. Costerton W., Veeh R., Shirtliff M., Pasmore M., Post C., Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112(10):1466-1477. DOI: 10.1172/JCI20365
  • 7. Davies D. Understanding biofilm resistance to antibacterial agents. Nat Rev Drug Discov. 2003;2(2):114-122. DOI: 10.1038/nrd1008
  • 8. Kolchanova N.E., Okulich V.K., Shilin V.E. Determination of the periodontal poket bacteria’s to form microbic communities and its chemical and biological objects resistance. Immunopathology, allergology, infectology. 2015;3:56-61. Russian. DOI: 10.14427/jipai.2015.3.56
  • 9. Ibberson C.B., Parlet C.P., Kwiecinski J., Crosby H.A., Meyerholz D.K., Horswill A.R. Hyaluronan modulation impacts Staphylococcus aureus biofilm infection. Infect Immun. 2016;84(6):1917-1929. DOI: 10.1128/IAI.01418-15
  • 10. Trizna E., Baidamshina D., Gorshkova A., Drucker V., Bogachev M., Tikhonov A., et al. Improving the efficacy of antimicrobials against biofilm-embedded bacteria using bovine hyaluronidase azoximer (Longidaza®). Pharmaceutics. 2021;13(11):1740. DOI: 10.3390/pharmaceutics13111740
  • 11. Stepanovic S., Vukovic D., Hola V., Di Bonaventura G., Djukic S., Cirković I., Ruzicka F. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS. 2007;115(8):891-899. DOI: 10.1111/j.1600-0463.2007.apm_630.x
  • 12. Saini H., Vadekeetil A., Chhibber S., Harjai K. Azithromycinciprofloxacin-impregnated urinary catheters avert bacterial colonization, biofilm formation, and inflammation in a murine model of foreign-body-associated urinary tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61(3):e01906-16. DOI: 10.1128/AAC.01906-16
  • 13. Andersen M.J., Flores-Mireles A.L. Urinary catheter coating modifications: the race against catheter-associated infections. Coatings. 2020;10:23. DOI: 10.3390/coatings10010023
  • 14. Cortese Y.J., Wagner V.E., Tierney M., Devine D., Fogarty A. Review of catheter-associated urinary tract infections and in vitro urinary tract models. J Healthc Eng. 2018;2018:2986742. DOI: 10.1155/2018/2986743
  • 15. Uruen C., Chopo-Escuin G., Tommassen J., MainarJaime R.C., Arenas J. Biofilms as promoters of bacterial antibiotic resistance and tolerance. Antibiotics. 2020;10(1):3. DOI: 10.3390/antibiotics1001003
  • 16. Hacioglu M., Oyardi O., Bozkurt-Guzel C., Savage P.B. Antibiofilm activities of ceragenins and antimicrobial peptides against fungal-bacterial mono and multispecies biofilms. J Antibiot. 2020;73:455-462. DOI: 10.1038/s41429-020-0299-0
  • 17. Weiland-Bräuer N., Malek I., Schmitz R.A. Metagenomic quorum quenching enzymes affect biofilm formation of Candida albicans and Staphylococcus epidermidis. PLoS One. 2019;14(1):e0211366. DOI: 10.1371/journal.pone.0211366
  • 18. Sharafutdinov I.S., Ozhegov G.D., Sabirova A.E., Novikova V.V., Lisovskaya S.A., Khabibrakhmanova A.M., et al. Increasing susceptibility of drug-resistant Candida albicans to fluconazole and terbinafine by 2(5H)-furanone derivative. Molecules. 2020;25(3):642. DOI: 10.3390/molecules25030642
  • 19. Thallinger B., Prasetyo E.N., Nyanhongo G.S., Guebitz G.M. Antimicrobial enzymes: an emerging strategy to fight microbes and microbial biofilms. Biotechnol J. 2013;8(1):97-109. DOI: 10.1002/biot.201200313
  • 20. Nahar S., Mizan M.F.R., Ha A.J.W., Ha S.D. Advances and future prospects of enzyme-based biofilm prevention approaches in the food industry. Compr Rev Food Sci Food Saf. 2018;17(6):1484-1502. DOI: 10.1111/1541-4337.12382
  • 21. Troshina N.A., Dolgushin I.I., Dolgushina V.F., Bakhareva L.I., Kurnosenko I.V., Nadvikova T.V. Effect of Longidaze on microbial landscape of cervical canal and uterine cavity during therapy of women with chronic nonspecific endometritis and uterus myoma. ZHurnal mikrobiologii, epidemiologii i immunobiologii. 2015;(4):71-74. Russian.
  • 22. Kulchavenya E.V., Shvetsova O.P., Breusov A.A. Rationale of use and effectiveness of Longidaza in patients with chronic prostatitis. Urology. 2018;4:64-71. Russian. DOI: 10.18565/urology.2018.4:64-71
  • 23. Gatina A., Trizna E., Kolesnikova A., Baidamshina D., Gorshkova A., Drucker V., et al. The bovhyaluronidase azoximer (Longidaza®) disrupts Candida albicans and Candida albicans-bacterial mixed biofilms and increases the efficacy of antifungals. Medicina. 2022;58(12):1710. DOI: 10.3390/medicina58121710
Views
0 Abstract
0 PDF
0 Crossref citations
Shared